Analyst Ratings for Alnylam Pharmaceuticals (ALNY) [Neutrals]
ALNY Rating Summary
ALNY Price Target Summary
- Highest: $395.00 (H.C. Wainwright)
- Lowest: $150.00 (Cantor Fitzgerald)
- Average: $224.89
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$224.89 (+56.4%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 67%
Avg. $ Target:
$224.89 (+56.4%)
* Over Last 12-Mos
Rating Score: 6.3 / 10
Percentile Rank: 67%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/16/2024 | Goldman Sachs | Salveen Richter | Downgrade | Neutral (Buy) |
173.00 (230.00) |
147.43 (143.80) |
-2.46% | Details |
| 2/14/2024 | Wolfe Research | Andy Chen | New Coverage | Peerperform (N/A) |
N/A (N/A) |
162.00 (143.80) |
-11.23% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
